Initially, reports describing miR-26 as a tumor suppressor because of its negative impact on myc-mediated transformation have been supported by studies that demonstrate its down-regulation in diverse cancer entities such as lymphoma, hepatocellular carcinoma, breast cancer and colorectal carcinoma (39, 40, 41, 42). Here, MYC is linked to breast cancer.